Drug Profile

NNC 0471 0119

Alternative Names: NN-1471; NNC 0471-0119; NNC0471-0119 H; Pumpsulin

Latest Information Update: 22 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novo Nordisk
Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

10 Jul 2025 Novo Nordisk plans a phase I trial in Type 2 diabetes mellitus (Treatment experienced) in Germany (SC) (NCT07068295)
28 Jan 2025 Phase-I clinical trials in Type 1 diabetes mellitus (In adults) in Germany (SC) (NCT06809621)
06 Feb 2024 NNC 0471 0119 is still in phase I trials for Type-1 diabetes mellitus in Austria (SC, Injection) (Novo Nordisk pipeline, February 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com